State Street Corp Has $363,000 Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB)

State Street Corp grew its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 12.9% during the third quarter, HoldingsChannel reports. The firm owned 383,248 shares of the biotechnology company’s stock after buying an additional 43,700 shares during the period. State Street Corp’s holdings in Seres Therapeutics were worth $363,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. Providence Wealth Advisors LLC lifted its stake in Seres Therapeutics by 49.5% in the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 25,250 shares during the period. Point72 DIFC Ltd acquired a new stake in Seres Therapeutics in the second quarter worth $64,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Seres Therapeutics in the second quarter valued at $92,000. Vontobel Holding Ltd. bought a new stake in Seres Therapeutics in the 3rd quarter valued at about $374,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after buying an additional 222,771 shares during the period. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Stock Performance

Shares of MCRB stock opened at $0.91 on Friday. The company has a market capitalization of $154.59 million, a price-to-earnings ratio of -3.94 and a beta of 2.07. Seres Therapeutics, Inc. has a 52-week low of $0.54 and a 52-week high of $2.05. The company has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $0.90.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. JPMorgan Chase & Co. cut shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, Chardan Capital restated a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.